Sinsin Pharmaceutical신신제약
002800 · KOSDAQ · ₩002800 · 신신제약
₩4,035▼ ₩15 (0.37%)End-of-day · Oct 27, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 39.1% | 37.9% | 34.0% | 32.6% | 33.0% | 29.4% |
| Operating margin | 11.8% | 9.5% | 6.5% | 5.9% | 5.9% | −1.8% |
| Net margin | 10.9% | 8.2% | 4.6% | 4.6% | 4.8% | −2.0% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +8.2% | +6.9% | +3.7% | +11.6% | +24.2% | — |
| Operating income growth | +34.7% | +56.6% | +14.8% | +10.6% | +504.2% | — |
| Net income growth | +44.9% | +90.1% | +4.5% | +6.0% | +399.1% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 17.5% | 13.2% | 7.6% | 7.7% | 7.7% | −2.7% |
| Return on assets | 8.3% | 7.0% | 3.8% | 3.8% | 3.7% | −1.3% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 79.3% | 84.5% | 97.5% | 100.4% | 103.6% | 108.6% |
| Net debt to equity | 46.8% | 53.2% | 68.3% | 70.9% | 69.0% | 82.5% |
| Current ratio | 106.8% | 98.4% | 87.1% | 91.1% | 106.4% | 107.5% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Sinsin Pharmaceutical / 신신제약 / 002800 / KRX:002800
Source: KRX statistical information